NCT03234153 - Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 15, 2018

Primary Completion Date

November 8, 2019

Study Completion Date

May 18, 2020

Conditions

Muscle-invasive Bladder Cancer

Interventions

DRUG

Durvalumab (Imfinzi)

Durvalumab 1500 mg i.v. every 4 weeks in combination with Tremelimumab 75 mg i.v. every 4 weeks for a total of 4 cycles before surgery.

DRUG

Tremelimumab

Tremelimumab 75 mg i.v. in combination with Durvalumab 1500 mg i.v. every 4 weeks every 4 weeks for a total of 4 cycles before surgery.

Trial Locations (1)

Departement of Medical Oncology, University Hospital Berne, Bern